Bimagrumab + GLP-1: The Muscle-Preservation Combination in Phase 3

The core combination concept

GLP-1 weight loss includes substantial lean-mass loss — typically 25-40% of total weight is lean mass. This is the most-discussed limitation of GLP-1 monotherapy and is roughly proportional to weight loss method generally (similar percentages occur with caloric restriction and bariatric surgery).

Bimagrumab targets the lean-mass-loss component pharmacologically. It blocks activin type II receptor (ActRIIB), the shared receptor through which myostatin and activin signal to suppress muscle growth. Blocking the receptor produces increased muscle mass in animal models — sometimes dramatically.

The combination concept: tirzepatide drives substantial fat loss; bimagrumab prevents the lean-mass loss component. The result theoretically: more fat loss with preserved or even increased muscle mass — a fundamentally different body composition outcome than either alone.

What Phase 2 showed

The BELIEVE Phase 2 trial (Heymsfield et al., JAMA Network Open 2021) tested bimagrumab vs. placebo in adults with type 2 diabetes and obesity over 48 weeks:

• Bimagrumab produced approximately 20.5% reduction in fat mass
• Bimagrumab produced approximately 3.6% increase in lean mass
• Placebo showed essentially flat lean mass
• Side effects were generally manageable

Subsequent studies have tested bimagrumab + semaglutide combinations. The combination produced better fat-vs-lean-mass partitioning than semaglutide alone — more fat loss, better lean mass preservation.

The Phase 2 results are striking because they suggest something unusual in obesity pharmacology: muscle increase during weight loss. Most weight-loss methods produce muscle decrease; bimagrumab inverts the pattern.

The Eli Lilly Phase 3 program

Eli Lilly acquired Versanis Bio (the previous bimagrumab developer) in 2023 specifically to advance bimagrumab into Phase 3 combination trials with tirzepatide. The strategic logic was clear — Lilly already had tirzepatide as the dominant GLP-1; adding bimagrumab would create a combination only Lilly could provide.

The Phase 3 program tests bimagrumab + tirzepatide in obesity, with primary endpoints including weight loss magnitude and body composition (DEXA or imaging-based fat vs. lean mass measurements). The combination's value proposition depends on the body composition data — if it's only slightly different from tirzepatide alone, the combination wouldn't justify the cost and complexity. If it's substantially better, it could reshape standard practice.

Readouts staggered through 2025-2027. Approval likely 2027-2028 if results hold.

The competing programs

Bimagrumab isn't alone in the muscle-preservation antibody space. Several competing approaches:

Apitegromab (Scholar Rock) — Selective for latent (pro-form) myostatin specifically. Phase 3 in spinal muscular atrophy with positive results, exploring obesity-related muscle preservation. Different selectivity profile than bimagrumab.

Trevogrumab (REGN1033, Regeneron) — Selective anti-myostatin antibody being studied in obesity-related muscle preservation contexts.

Garetosmab and others — earlier-stage candidates in the broader space.

The competing programs have different selectivity profiles — some target latent myostatin specifically, others target the receptor more broadly. The Phase 3 outcomes will determine which approach proves most clinically valuable.

What approval would mean

If bimagrumab + tirzepatide is approved with substantially better body composition than tirzepatide alone:

Standard of care shift. Combination therapy could become first-line for moderate-to-severe obesity, particularly in patients prioritizing lean-mass preservation.

Cost implications. Combination products are typically more expensive. Insurance coverage for combination obesity therapy will be a substantial question.

Older adults and sarcopenia. Patients particularly vulnerable to lean-mass loss (older adults, post-menopausal women, patients with already-low muscle mass) would benefit most.

Athletes and active populations. The body composition focus would appeal to populations who prioritize maintaining or increasing strength alongside weight management.

Reframing of GLP-1 lean-mass loss. The concern that has dominated some fitness-community discussions about GLP-1 medications would be substantially addressed by pharmacological solution.

Risks and unknowns

Several open questions:

Long-term safety. Bimagrumab affects pathways beyond muscle alone. ActRIIB blockade has potential effects on bone, cardiovascular tissue, and endocrine signaling. Long-term safety data is limited.

Phase 3 translation. Phase 2 magnitudes don't always hold in Phase 3. The combination's value proposition depends on Phase 3 confirming the body composition advantage at scale.

Cardiovascular outcomes. Bimagrumab adds biology beyond GLP-1's well-characterized cardiovascular benefits. Whether the combination preserves or modifies the GLP-1 cardiovascular advantage is part of what Phase 3 will reveal.

Practical access. Combination therapy adds complexity and cost. How widely accessible the combination becomes depends on payer dynamics.

Implications for current patients

If you're currently on GLP-1 monotherapy:

• No reason to wait for bimagrumab. Current options (semaglutide, tirzepatide) are highly effective.
• Resistance training and protein intake remain the evidence-based muscle-preservation interventions today.
• Bimagrumab + GLP-1 may become a future option worth considering — particularly if you've prioritized lean-mass preservation throughout therapy.
• Don't substitute future combination therapy for current behavioral interventions. The behavioral foundation (resistance training, protein) matters regardless of pharmacological approach.